940 related articles for article (PubMed ID: 36747242)
1. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
[TBL] [Abstract][Full Text] [Related]
2. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
5. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
[TBL] [Abstract][Full Text] [Related]
6. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Mori K; Abufaraj M; Mostafaei H; Quhal F; Fajkovic H; Remzi M; Karakiewicz PI; Egawa S; Schmidinger M; Shariat SF; Gust KM
Eur Urol; 2021 Jun; 79(6):783-792. PubMed ID: 33172722
[TBL] [Abstract][Full Text] [Related]
7. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
[TBL] [Abstract][Full Text] [Related]
8. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 detection using
Vento J; Mulgaonkar A; Woolford L; Nham K; Christie A; Bagrodia A; de Leon AD; Hannan R; Bowman I; McKay RM; Kapur P; Hao G; Sun X; Brugarolas J
J Immunother Cancer; 2019 Jun; 7(1):144. PubMed ID: 31155004
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.
Zhong YM; Yin K; Chen Y; Xie Z; Lv ZY; Yang JJ; Yang XN; Zhou Q; Wang BC; Zhong WZ; Gao LL; Zhou WB; Chen J; Tu HY; Liao RQ; Zhang DK; Zhang SL; Lu DX; Zheng HB; Zhang HH; Wu YL; Zhang XC
Front Immunol; 2022; 13():951817. PubMed ID: 36263036
[TBL] [Abstract][Full Text] [Related]
11. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
Front Immunol; 2020; 11():624547. PubMed ID: 33552089
[TBL] [Abstract][Full Text] [Related]
12. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
Front Immunol; 2021; 12():731546. PubMed ID: 34484242
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective.
Lavacchi D; Pellegrini E; Palmieri VE; Doni L; Mela MM; Di Maida F; Amedei A; Pillozzi S; Carini M; Antonuzzo L
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32630154
[TBL] [Abstract][Full Text] [Related]
15. ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies.
Matsumoto A; Nakashima C; Kimura S; Sueoka E; Aragane N
BMC Cancer; 2021 May; 21(1):584. PubMed ID: 34022841
[TBL] [Abstract][Full Text] [Related]
16. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
Singh N; Temin S; Baker S; Blanchard E; Brahmer JR; Celano P; Duma N; Ellis PM; Elkins IB; Haddad RY; Hesketh PJ; Jain D; Johnson DH; Leighl NB; Mamdani H; Masters G; Moffitt PR; Phillips T; Riely GJ; Robinson AG; Rosell R; Schiller JH; Schneider BJ; Spigel DR; Jaiyesimi IA
J Clin Oncol; 2022 Oct; 40(28):3323-3343. PubMed ID: 35816668
[TBL] [Abstract][Full Text] [Related]
17. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
18. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.
Hong L; Negrao MV; Dibaj SS; Chen R; Reuben A; Bohac JM; Liu X; Skoulidis F; Gay CM; Cascone T; Mitchell KG; Tran HT; Le X; Byers LA; Sepesi B; Altan M; Elamin YY; Fossella FV; Kurie JM; Lu C; Mott FE; Tsao AS; Rinsurongkawong W; Lewis J; Gibbons DL; Glisson BS; Blumenschein GR; Roarty EB; Futreal PA; Wistuba II; Roth JA; Swisher SG; Papadimitrakopoulou VA; Heymach JV; Lee JJ; Simon GR; Zhang J
J Thorac Oncol; 2020 Sep; 15(9):1449-1459. PubMed ID: 32389639
[TBL] [Abstract][Full Text] [Related]
19. Investigation of response factors for monotherapy with immune checkpoint inhibitors in non-small cell lung cancer patients with PD-L1 expression <50.
Takahara Y; Abe R; Sumito N; Tanaka T; Ishige Y; Shionoya I; Yamamura K; Nishiki K; Nojiri M; Kato R; Shinomiya S; Oikawa T
Thorac Cancer; 2023 Sep; 14(27):2754-2760. PubMed ID: 37536667
[TBL] [Abstract][Full Text] [Related]
20. A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma.
An Z; Hsu MA; Gicobi JK; Xu T; Harrington SM; Zhang H; Pavelko KD; Hirdler JB; Lohse CM; Nabavizadeh R; Pessoa RR; Sharma V; Thompson RH; Leibovich BC; Dong H; Lucien F
J Immunol; 2023 Jun; 210(12):2029-2037. PubMed ID: 37163328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
